Trial Profile
Verorab(R) Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Rabies vaccine (Primary) ; Rabies immune globulin
- Indications Rabies
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi Pasteur
- 09 Apr 2020 Results published in the Vaccine
- 16 Mar 2019 Results comparing seroconversion rate at Day14 between two vaccination regimens published in the Vaccine
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.